rs2236224 — MTHFD1 MTHFD1 R653Q

MTHFD1 R653Q — When the Folate Relay Falters at the Purine Synthesis Step

MTHFD1 (methylenetetrahydrofolate dehydrogenase 1) is a remarkable trifunctional enzyme: a single polypeptide that catalyzes three sequential reactions converting folate derivatives along a one-carbon relay chain. Its three enzyme domains — dehydrogenase, cyclohydrolase, and formyltetrahydrofolate synthetase¹¹ dehydrogenase, cyclohydrolase, and formyltetrahydrofolate synthetase
The three catalytic domains work in sequence: dehydrogenase oxidizes 5,10-methylene-THF, cyclohydrolase converts to 5,10-methenyl-THF, and synthetase attaches a formyl group to produce 10-formylTHF — collectively produce the 10-formylTHF used to synthesize purines from scratch. Purines are the building blocks of DNA and RNA, making MTHFD1 essential wherever cells divide rapidly: during neural tube closure, cardiac development, and early pregnancy.

The R653Q variant (rs2236225, G>A, p.Arg653Gln) lies in the 10-formylTHF synthetase domain — the third of MTHFD1's three catalytic units. The rs2236224 variant profiled here is an intronic marker (c.2136+31G>A) in strong linkage disequilibrium with R653Q, and is tracked alongside rs2236225 in association studies. The two SNPs sit 306 bp apart on chromosome 14 and are statistically coupled: publications from the Women's Health Initiative (PMID 34967850) report both variants together in association analyses.

The Mechanism

The arginine-to-glutamine substitution at position 653 alters the surface charge of the synthetase domain, which destabilizes the folded protein²² destabilizes the folded protein
Rao et al. 2023 showed R653Q MTHFD1 binds more strongly to the E3 ubiquitin ligase TRIM21, triggering accelerated degradation through ubiquitination at lysine K504. The variant enzyme is tagged for faster destruction via the proteasomal pathway, reducing the steady-state abundance of functional MTHFD1 protein in cells. The downstream consequence is reduced 10-formylTHF availability, which impairs the two formyl-transfer steps in de novo purine biosynthesis³³ de novo purine biosynthesis
De novo purine synthesis: the pathway cells use to build purines (adenine, guanine) from scratch rather than recycling them. Ten-formylTHF donates the C2 and C8 carbon atoms of the purine ring. Cells with less MTHFD1 activity must redirect more folate toward remethylation reactions, creating a metabolic competition between purine synthesis and homocysteine clearance.

The Evidence

The R653Q variant has its most robust evidence in maternal reproductive health. Brody et al. (2002)⁴⁴ Brody et al. (2002)
Brody LC et al. A polymorphism, R653Q, in the trifunctional enzyme MTHFD1 is a maternal genetic risk factor for neural tube defects. Am J Hum Genet, 2002 identified QQ-homozygous mothers as having an OR of 1.52 (95% CI 1.16–1.99, p=0.003) for having a child with a neural tube defect in an Irish population of 410 NTD-affected mothers and 997 controls. The QQ genotype frequency was 26% in NTD mothers vs 19% in controls. Critically, child genotype was not associated — only maternal genotype matters, because the developing embryo depends entirely on the mother's folate metabolism in early pregnancy.

A meta-analysis of 9 studies totalling 4,302 NTD cases and 4,238 controls⁵⁵ meta-analysis of 9 studies totalling 4,302 NTD cases and 4,238 controls
Jiang J et al. Association between MTHFD1 G1958A polymorphism and neural tube defects susceptibility: a meta-analysis. PLoS One, 2014 confirmed this maternal-specific effect, reporting a pooled OR of 1.17 (p=0.001) for the AA vs GG comparison in Caucasian populations. The association held across all genetic models tested (additive, recessive, dominant), and no effect was detected in NTD cases or their fathers — underscoring that this is a maternal folate-efficiency variant, not a direct embryonic gene.

Beyond NTDs, Parle-McDermott et al. (2005)⁶⁶ Parle-McDermott et al. (2005)
Parle-McDermott A et al. MTHFD1 R653Q is a maternal genetic risk factor for severe abruptio placentae. Am J Med Genet A, 2005 found QQ mothers had nearly three times the odds of severe placental abruption (OR 2.85, 95% CI 1.47–5.53, p=0.002) compared to RR/RQ mothers — an association not seen with MTHFR variants in the same dataset, suggesting MTHFD1 R653Q tags an independent folate metabolism vulnerability.

On the mechanistic side, Rao et al. (2023)⁷⁷ Rao et al. (2023)
Rao K et al. The negative effect of G1958A polymorphism on MTHFD1 protein stability and HCC growth. Cell Oncol, 2023 demonstrated that the R653Q protein is degraded faster than wild-type MTHFD1 through TRIM21-mediated ubiquitination, resulting in reduced IMP (inosine monophosphate) production — a marker of impaired purine synthesis. Adding exogenous adenosine rescued cell growth in R653Q-expressing cells, confirming purine synthesis impairment as the functional bottleneck.

Practical Actions

For most people the R653Q variant is manageable through folate and choline optimization. The key difference from MTHFR variants is that MTHFD1 R653Q primarily constrains purine synthesis (via 10-formylTHF) rather than methylation (via methylfolate). Both arms of folate metabolism are stressed, however, because the enzyme also affects the folate pool available for homocysteine remethylation.

A mouse model study⁸⁸ mouse model study
Christensen KE et al. Mild choline deficiency and MTHFD1 synthetase deficiency interact to increase incidence of developmental delays and defects. Nutrients, 2021 showed that mild choline deficiency sharply amplifies the developmental risk of MTHFD1 synthetase deficiency, with embryos showing open neural tubes, reversed heart looping, and facial malformations when both variables were present. Choline and folate share the one-carbon pool — both are used to remethylate homocysteine — so MTHFD1 R653Q carriers appear especially sensitive to choline shortfalls. Notably, most women (80–90%) do not reach the Adequate Intake for choline.

Interactions

MTHFD1 R653Q and MTHFR C677T (rs1801133) affect adjacent but distinct steps in folate metabolism: MTHFD1 supplies the purine-synthesis arm while MTHFR converts folate for methylation. Carriers of both may face more comprehensive folate-pathway impairment than either variant alone suggests. The SLC19A1 folate transporter (rs1051266, rs1051298) determines how much folate enters cells; impaired transport compounds the effect of reduced MTHFD1 efficiency. Because choline can partially substitute for folate in homocysteine remethylation via betaine, adequate choline intake is especially important when MTHFD1 capacity is reduced.